A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

NCT04184622 on ClinicalTrials.gov · last registry update 2025-07-24

An unusually large phase 3: 2,539 participants, more than double the 424 typical for the stage. The sponsor logged completion for 1 April 2022. Primary outcome, as filed: Percent Change From Baseline in Body Weight (Primary Treatment Period). tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 2,539
Started: 2019-12-04
Primary completion: 2022-04-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change From Baseline in Body Weight (Primary Treatment Period)

Conditions studied

Overweight · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.